Vaxcyte will report 2025 financial results and host a conference call on February 24, 2026.
Quiver AI Summary
Vaxcyte, Inc. has announced that it will release its financial results for the fourth quarter and full year of 2025 on February 24, 2026, after market close. The company will also provide a business update during a conference call and webcast at 4:30 p.m. ET. Vaxcyte is focused on innovating vaccines to combat bacterial diseases, with candidates like VAX-31 and VAX-24 aimed at preventing invasive pneumococcal disease. These candidates utilize advanced technology to cover more serotypes than current vaccines, addressing critical health issues such as antibiotic resistance. Vaxcyte is also developing vaccines for Group A Strep and Shigella, and employs a proprietary cell-free protein synthesis platform to enhance vaccine production. Additional details can be found on their website.
Potential Positives
- Vaxcyte will provide a financial results update for Q4 and the full year 2025, indicating transparency and engagement with investors.
- The company's advanced vaccine candidates, VAX-31 and VAX-24, position it as a leader in addressing invasive pneumococcal disease with the broadest-spectrum formulations in clinical trials.
- The use of the XpressCF® platform demonstrates innovative technology that could improve the efficiency and effectiveness of vaccine development.
- Vaxcyte's pipeline includes promising candidates for preventing Group A Strep infections and Shigella, highlighting the company's commitment to addressing significant public health challenges.
Potential Negatives
- Limited information on financial results and business updates may indicate potential challenges or uncertainties for the company.
- The press release focuses heavily on the pipeline candidates but does not mention any recent successes, which may raise concerns about current product development status.
- Absence of specific timelines or projections for clinical trials could imply a lack of progress in development and potential delays ahead.
FAQ
When will Vaxcyte report its financial results for 2025?
Vaxcyte will report its financial results for the fourth quarter and full year 2025 on February 24, 2026.
How can I participate in the Vaxcyte conference call?
To participate in the conference call, dial 800-445-7795 (domestic) or 785-424-1699 (international) using conference ID PCVX4Q25.
Where can I find the live webcast of the conference call?
The live webcast will be available in the Investors & Media section of Vaxcyte’s website at www.vaxcyte.com.
What is Vaxcyte's main focus in vaccine innovation?
Vaxcyte focuses on engineering high-fidelity vaccines to protect against bacterial diseases, including invasive pneumococcal disease.
What are Vaxcyte's key vaccine candidates currently in development?
Key candidates include VAX-31, VAX-24, VAX-A1, and VAX-GI, targeting invasive pneumococcal disease and other infections.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PCVX Insider Trading Activity
$PCVX insiders have traded $PCVX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $PCVX stock by insiders over the last 6 months:
- ELVIA COWAN (SVP, FINANCE) has made 0 purchases and 2 sales selling 11,623 shares for an estimated $556,971.
- HARPREET S. DHALIWAL (Chief Technical Ops Officer) sold 9,743 shares for an estimated $454,890
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PCVX Hedge Fund Activity
We have seen 149 institutional investors add shares of $PCVX stock to their portfolio, and 147 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 3,928,808 shares (-82.3%) from their portfolio in Q3 2025, for an estimated $141,515,664
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,314,171 shares (+38.6%) to their portfolio in Q3 2025, for an estimated $83,356,439
- JANUS HENDERSON GROUP PLC removed 1,587,141 shares (-10.8%) from their portfolio in Q3 2025, for an estimated $57,168,818
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,481,764 shares (-46.7%) from their portfolio in Q3 2025, for an estimated $53,373,139
- D. E. SHAW & CO., INC. added 1,202,340 shares (+38.9%) to their portfolio in Q3 2025, for an estimated $43,308,286
- CITADEL ADVISORS LLC removed 884,939 shares (-81.1%) from their portfolio in Q3 2025, for an estimated $31,875,502
- DEEP TRACK CAPITAL, LP added 850,000 shares (+39.5%) to their portfolio in Q3 2025, for an estimated $30,617,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PCVX Analyst Ratings
Wall Street analysts have issued reports on $PCVX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 02/02/2026
- Needham issued a "Buy" rating on 01/07/2026
- BTIG issued a "Buy" rating on 11/10/2025
To track analyst ratings and price targets for $PCVX, check out Quiver Quantitative's $PCVX forecast page.
$PCVX Price Targets
Multiple analysts have issued price targets for $PCVX recently. We have seen 4 analysts offer price targets for $PCVX in the last 6 months, with a median target of $97.5.
Here are some recent targets:
- Seamus Fernandez from Guggenheim set a target price of $116.0 on 02/02/2026
- Joseph Stringer from Needham set a target price of $110.0 on 01/07/2026
- Thomas Shrader from BTIG set a target price of $85.0 on 11/10/2025
- Asad Haider from Goldman Sachs set a target price of $38.0 on 09/12/2025
Full Release
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT.
To participate in the conference call, please dial 800-445-7795 (domestic) or 785-424-1699 (international), conference ID PCVX4Q25. A live webcast of the conference call will be available in the Investors & Media section of the Company’s website at www.vaxcyte.com . A replay of the webcast will be available for approximately 30 days following the conference call.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in a Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com .
Contacts:
Patrick Ryan, Executive Director, Corporate Affairs
Vaxcyte, Inc.
415-606-5135
[email protected]
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
[email protected]
